PCSK—9抑制剂在治疗高胆固醇血症方面的研究进展(4)
[11]胥雪莲，何川.前蛋白转化酶枯草溶菌素9与动脉粥样硬化[J].心血管病学进展，2016，1(37)：50-53.
[12]Rashid S，Curtis DE，et al.Decreased plama cholesterol and hypersensitivity to statins inmice lacking PCSK9[J].Proc Natl Acad Sci USA，2005，102(15)：5374-5379.
[13]Frank-Kamenetsky M，Grefhorst A，et al.Therapeutic RNAi targeting PCSK9 acutely lowersplasma cholesterol inrodents and LDL cholesterol innonhumanprimates[J].Proc Natl Acad Sci USA，2008，105(30)：11915-11920.
, 百拇医药
[14]冯丹阳，王立明.PCSK9的发现和进展[J].河北医药，2016，5(38)：759-762.
[15]Joseph L， Robinson J，et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibition and the Future of Lipid Lowering Therapy[J].Progress in Cardiovascular Diseases，2015，19(31)：19-31.
[16]Cannon C， Cariou B，et al. Efficacy and safety of Alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated dosesof statins： the ODYSSEY COMBO II randomized controlled trial[J].European Heart Journal，2015，36(19)：1186-1194.
, 百拇医药
[17]Roth EM， Taskinen MR，et al. Monotherapy with the PCSK-9 inhibitorAlirocumab versusezetimibein patientswith hypercholesterolemia： results of a 24 week， double-blind， randomized Phase 3 trial[J].Int J Cardiol，2014，176(1)：55-61.
[18]Kastelein JJ， Robinson JG，et al. Efficacy and safety of Alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy： design and rationale of the ODYSSEY FH studies[J].Cardiovasc Drugs Ther，2014 ，28(3)：281-289.
, http://www.100md.com
[19]Stroes E， Colquhoun D，et al. Anti-PCSK-9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance[J].Journal of the American College of Cardiology，2014，63(23)：2541-2548.
[20]Koren MJ， Giugliano RP，et al. Efficacy and safety of longer-term administration of Evolocumab (AMG 145) in patients with hypercholesterolemia： 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial[J].Circulation，2014，129(2)：234-243.
, 百拇医药
[21]Raal F， Scott R，et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145， a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia： the Reduction of LDL-C with PCSK-9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial[J].Circulation，2012，126(20)：2408-2417.
[22]Xiang Wang， Evan Berry，et al.MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells[J].FEBS LETTERS，2015，589(14)：490-496.
編辑/成森, 百拇医药(杨晓娜 孟照辉)
[12]Rashid S，Curtis DE，et al.Decreased plama cholesterol and hypersensitivity to statins inmice lacking PCSK9[J].Proc Natl Acad Sci USA，2005，102(15)：5374-5379.
[13]Frank-Kamenetsky M，Grefhorst A，et al.Therapeutic RNAi targeting PCSK9 acutely lowersplasma cholesterol inrodents and LDL cholesterol innonhumanprimates[J].Proc Natl Acad Sci USA，2008，105(30)：11915-11920.
, 百拇医药
[14]冯丹阳，王立明.PCSK9的发现和进展[J].河北医药，2016，5(38)：759-762.
[15]Joseph L， Robinson J，et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibition and the Future of Lipid Lowering Therapy[J].Progress in Cardiovascular Diseases，2015，19(31)：19-31.
[16]Cannon C， Cariou B，et al. Efficacy and safety of Alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated dosesof statins： the ODYSSEY COMBO II randomized controlled trial[J].European Heart Journal，2015，36(19)：1186-1194.
, 百拇医药
[17]Roth EM， Taskinen MR，et al. Monotherapy with the PCSK-9 inhibitorAlirocumab versusezetimibein patientswith hypercholesterolemia： results of a 24 week， double-blind， randomized Phase 3 trial[J].Int J Cardiol，2014，176(1)：55-61.
[18]Kastelein JJ， Robinson JG，et al. Efficacy and safety of Alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy： design and rationale of the ODYSSEY FH studies[J].Cardiovasc Drugs Ther，2014 ，28(3)：281-289.
, http://www.100md.com
[19]Stroes E， Colquhoun D，et al. Anti-PCSK-9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance[J].Journal of the American College of Cardiology，2014，63(23)：2541-2548.
[20]Koren MJ， Giugliano RP，et al. Efficacy and safety of longer-term administration of Evolocumab (AMG 145) in patients with hypercholesterolemia： 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial[J].Circulation，2014，129(2)：234-243.
, 百拇医药
[21]Raal F， Scott R，et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145， a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia： the Reduction of LDL-C with PCSK-9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial[J].Circulation，2012，126(20)：2408-2417.
[22]Xiang Wang， Evan Berry，et al.MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells[J].FEBS LETTERS，2015，589(14)：490-496.
編辑/成森, 百拇医药(杨晓娜 孟照辉)
参见：首页 > 医学版 > 医学知识 > 代谢&生命 > 胆固醇